Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention provides methods of modulating or inhibiting microglia activation comprising the administration of a compound capable of inhibiting 5-LOX, FLAP, attenuating degradation of I&kgr;B&agr; or inhibiting nuclear translocation of the NF-&kgr;B active complex for the treatment of Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain.

Abstract: The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

Abstract: Thiosemicarbazone compounds of formula: 1

Abstract: This invention relates to a series of difluoromethylene aromatic ethers of the formula 1

Abstract: The present invention provides methods of modulating or inhibiting microglia activation comprising the administration of a compound capable of inhibiting 5-LOX, FLAP, attenuating degradation of IKB&agr; or inhibiting nuclear translocation of the NF-KB active complex for the treatment of Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain.

Abstract: The present invention is a novel intermediate, compound of the formula (VI) 1

Abstract: The present invention is concerned with an anti-inflammation analgesic preparation which contains a specific 3-0-substituted ascorbic acid as an active ingredient, shows excellent anti-inflammation analgesic effects and is excellent in shelf life, safety to a skin and endermic absorptivity of the active ingredient.

Abstract: A water-in-oil emulsion containing ascorbic acid and, as an emulsifier, a dimethiconecopolyol or an alkyldimethiconecopolyol, where the aqueous phase having a pH ranging from 5.5 to 7.5. This emulsion allows ascorbic acid to be stabilized and can be used, in particular, in the cosmetics and/or dermatological fields. The invention also relates to a cosmetic process for treating the skin using the emulsion.

Abstract: The invention provides novel adamantane compounds having one of the following formulas: 1

Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.

Abstract: The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acid compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5-4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.

Abstract: A method and composition for treating patients with viral infection with pharmaceutical agents is disclosed. In one embodiment, the virus is influenza A and the pharmaceutical agent is rimantadine or amantadine. The methods of the present invention can be used as a way of eradicating influenza virus topically by direct administration of a dose—nasally—that is much lower than an oral therapeutic dose. Thereby avoiding the side effects associated with oral administration.

Abstract: A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.

Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides, such as rhGH. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration, are provided, and methods of preparation of the modified amino acid compound are provided.

Abstract: The present invention relates to an active ingredient preparation comprising ibuprofen, to a process for its production, to its use for producing pharmaceutical preparations and solid dosage forms, and to pharmaceutical preparations and solid dosage forms comprising the ibuprofen active ingredient preparation.

Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: 1

Abstract: Provided, among other things, are methods for treating mammals, such as humans, with diabetes mellitus to delay the onset of end stage renal disease, relating to administering an effective amount of a pharmaceutical composition, wherein said composition comprise, a compound selected from the group consisting of aminoguanidine, its pharmaceutically acceptable salts, and mixtures thereof. Methods are disclosed for the gradual administration of the compound for treatment of diabetes or other indications associated with damage caused by reducing sugars, for the use of a periodic screening test for crescentic glomerulonephritis, and for treating humans with indicia of overt diabetic nephropathy.

Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.

Abstract: Disclosed is method for reducing myocardial cell damage during and/or after percutaneous coronary intervention in a subject's coronary artery. The method includes instilling a beta blocker directly into the subject's coronary artery prior to percutaneous coronary intervention. A kit for carrying out percutaneous coronary intervention is also disclosed. The kit includes a catheter and a beta blocker.

Abstract: Norepinephrine reuptake inhibitors are used to treat psoriasis.

Abstract: This application relates to the use of certain amines of formula (I) 1

Abstract: A solvent system for the solution in a polar solvent of a poorly soluble compound having pharmacological activity is disclosed that comprises a first polar organic material comprising a sugar having at least two hydroxyl groups or an alcohol of two or three carbons having at least two hydroxyl groups or both and a second polar organic material comprising an amide group or an ammonium group or both., such as, one or more of acetamide, ethylammonium nitrate, N-methylacetamide and dimethylacetamide, preferably an amide.

Abstract: A foaming apparatus and method according to which a mixture of gas and a liquid is introduced into a vessel at a predetermined velocity and passes through a passage in the vessel. The flow of the mixture through the passage is increased to increase the velocity of the mixture and cause corresponding shearing forces on the mixture to create a turbulance and form foam from the mixture. The restrictor can be moved in the passage to vary the amount of restriction and therefore the amount of the foam.

Abstract: An emulsifier mixture comprising an emulsifier I of the formula 1

Abstract: An oiliness agent comprising a carboxylate of a composite metal hydroxide having a chemical composition represented by the following general formula (1),

Abstract: The present invention discloses a process for converting synthesis gas into hydrocarbonaceous products including the steps of: (a) subjecting a first portion of synthesis gas to a dual functional syngas conversion process to form a first effluent comprising a first hydrocarbonaceous product including aromatics and iso-paraffins; (b) subjecting a second portion of synthesis gas to a Fischer-Tropsch synthesis process to form a second effluent comprising a second hydrocarbonaceous product including linear paraffins and linear olefins; and (c) alkylating the linear olefins with the iso-paraffins to produce high octane gasoline range alkylate.

Abstract: A polymeric sponge includes cellulose fibers imbedded therein. The sponge is made by mixing water and cellulose fibers with a water-catalyzing prepolymer for chemical reaction thereof. The mixture is cured and granulated to size. The cellulose fibers enhance both the manufacturing process and the resulting sponge for increasing strength, durability, and performance thereof.

Abstract: The invention relates to flame-resistant HR cold-cure moulded foams with reduced smoke intensity and toxicity, a process for the preparation thereof and the use thereof.

Abstract: The present invention is a low density polyurethane foam cushion useful as an attached carpet cushion or as a detached carpet underlay. The low density foams of the present invention are prepared by a process wherein a polyurethane foam formulation is blown by both mechanical and chemical processes.

Abstract: A process for producing a flexible polyurethane foam satisfying low resilience, high vibration absorption and high durability, is presented. A mixture comprising from 95 to 50 mass % of a polyoxyalkylene polyol produced by means of an alkali metal catalyst and from 5 to 50 mass % of a polyoxyalkylene polyol produced by means of a double metal cyanide complex catalyst, is reacted with a polyisocyanate compound in the presence of a catalyst and a blowing agent, to produce a flexible polyurethane foam having a resonance frequency of at most 3.7 Hz, a resonance ratio of at most 3.5 and an impact resilience of at most 70%.

Abstract: The present invention discloses an ultraviolet light curable transparent conductive composition and method for making such a composition that may be used to produce a transparent conductive coating on a suitable substrate. These coatings may be used in such applications as touch screens, membrane switches, TV screens, and VCRs. The disclosed composition does not contain any significant amount of volatile organic solvents that do not become incorporated in the active layer after curing.

Abstract: Methods of forming crosslinked polymer particles in situ from polymer precursors such as monomers or oligomers, comprising exposing a composition comprising at least one polymer precursor, a solvent or solvent mixture, and an antisolvent or antisolvent mixture to photoradiation under conditions whereby particles are formed are provided. The polymer precursor may be photosensitive, or a separate polymerization initiator may be used. In a preferred embodiment, the polymer precursor is insoluble in the antisolvent or antisolvent mixture and the solvent or solvent mixture is soluble in the antisolvent or antisolvent mixture at the concentrations used. Crosslinked polymer particles and crosslinked polymer particles comprising a polymer and a bioactive material are also provided. The polymer may be erodable, and the polymer particles formed may be used in a variety of applications, including controlled release of bioactive materials such as drugs.

Abstract: A radiation curable coating composition includes a mixture of an oligomeric acrylate having a crosslinkable acrylate functionality of 1 to 6, at least one of monomeric acrylates and dimeric acrylates, having a crosslinkable acrylate functionality of 1 to 6, an acrylated colloidal silica, and a photoinitiator.

Abstract: A fast-curing, low viscosity composition for coating an optical waveguide, more specifically, an optical fiber, and optical fibers coated therewith are disclosed. The coating composition is a radiation curable composition containing: a radiation curable oligomer, a free radical photoinitiator, and a mixture of reactive diluents including a low molecular weight (meth)acrylate having tri-, tetra-, penta- or higher functionality.

Abstract: The invention disclosed includes a coating composition for siliceous surfaces. The coating includes at least one component from the group consisting of poly(alkoxy)silane, poly(halo)silane, alkoxysilane, halosilane, and mixtures thereof and a catalyst compound which generates a proton to hydrolyze the component when exposed to radiation. Preferably, the catalyst is a photo-acid. The invention also includes a method of coating the optical fiber. The aforementioned coating is applied to an exterior surface of the fiber. A proton is generated to promote the hydrolysis of the component. The invention further includes a method of accelerating adhesion between the exterior surface of the article and the coating. The inventive coating is applied to the surface of the fiber and the coating is exposed to a radiation source.

Abstract: There is provided a radiation-curable coating composition containing oligomers that each have two end groups X1 and X2, wherein the end groups X1 and X2, which may be the same or different, are a photoinitiator group or an adhesion promoter group. The coating composition may exclude the presence of non-reactive photoinitiator groups and non-reactive adhesion promoter groups, each of which would fail to covalently bond itself to an oligomer backbone.

Abstract: The present invention employs a dissolved activated polyethylene glycol (aPEG) or related molecule that has been passed through a filtration means for the substantial reduction of bioburden or endotoxin levels in the aPEG solution. The resulting filtered aPEG solution can be used for the preparation of a PEGylated hemoglobin solution containing substantially reduced levels of bioburden or endotoxin.

Abstract: The present invention discloses a method for enhancing the wear-resistance of polymers by crosslinking them, especially before irradiation sterilization. In particular, this invention presents the use of chemically crosslinked ultrahigh molecular weight polyethylene in in vivo implants.

Abstract: Dental root canal filling cones are prepared from a filler and a thermoplastic polymer, wherein the thermoplastic polymer is formed by polymerization of polymerizable diepoxide monomer and amine monomer. The amine monomers are primary monoamine and/or a disecondary diamine. The filler has about 40 to 90 weight-% of the cones providing a radio-opacity of at least 3 mm/mm aluminum.

Abstract: Compositions comprising a base fluid and a monoester copolymer of styrene and maleic anhydride are disclosed. The compositions can further comprise an alkyl orthophosphate ester. The base fluid can be an aqueous or organic base fluid. The monoester copolymer is at least partially soluble or dispersible in the base fluid. Preferably, the composition may further include a cross-linking agent capable of increasing the viscosity of the composition, such as aluminum isopropoxide or other metal source compounds. The composition can form a gel which is stable at a temperature of about 250° F. (121° C.) or higher. Some gels of the present invention exhibit stability up to about 300° F. (149° C.) to 350° F. (177° C.) or higher. The compositions have many applications, such as pipeline treatment, conformance, hydraulic fracturing, well completion, gravel packing, drilling fluids, process facility treatment fluids, and other well treatment applications.

Abstract: The invention provides a friction material containing a fibrous reinforcement, a friction modifier, and a binder as major components, which does not contain asbestos fibers but contains, as an organic friction modifier, para-, meta- and meta-para-type aramide resin dusts independently or as a mixture thereof. It is preferred to mix the para-type and m-type aramide resin dusts independently or as a mixture in an amount of 1 to 60% by volume based on the volume of the whole friction material.

Abstract: An oil-based ballpoint pen ink composition comprising a) a colorant, b) a solvent containing one or more solvents having the following chemical structural formula (1) 1

Abstract: An ink composition for sensing carbon dioxide gas contains a pH indicator, binder, and solvent and allows easy visual observation of color changes of an indicating portion caused by the concentration of carbon dioxide gas. When this ink composition is applied to a carbon dioxide indicator and package, a pinhole and poor seal of a gas-replaced package sealing a replacement gas which contains carbon dioxide gas are easily found.

Abstract: A process for synthesizing copolymers of ethylenically unsaturated monomers with ethylenically unsaturated derivatives of fatty acids and/or oils via emulsion polymerization techniques is performed in two stages. One or more suitable ethylenically unsaturated monomers are polymerized in the first stage of an emulsion polymerization. The ethylenically unsaturated derivatives of fatty acids and/or oils are blended with other monomers and polymerized in a second stage of the polymerization reaction. A suitable surfactant is added to the polymerization mixture to facilitate formation of the emulsion. In a preferred embodiment, the surfactant is a hybrid surfactant, i.e., one having both anionic and non-ionic characteristics.

Abstract: Biopolymers and biopolymer blends, including block copolymers, prepared via enzyme-mediated catalysis preferably in a microorganism host in which the reaction conditions are selected to produce biopolymers and biopolymer blends having particular chemical compositions and microstructures.

Abstract: A process of making a pigmented shaped article comprising: (a) providing polytrimethylene terephthalate chips and two or more colored pigmented chips each containing at least one different color pigment; (b) heating the polytrimethylene terephthalate chips and colored pigmented chips to a temperature of about 200—about 280° C. to melt the chips and form a polymer composition comprising the polytrimethylene terephthalate and at least one color pigment; and (c) forming a shaped article from the polymer composition.

Abstract: Described are imbibition compositions that incorporate kinetic enhancing additive(s) into photochromic polymeric host material. Kinetic enhancing additives include organic polyol(s), epoxy-containing compound(s) or a mixture thereof that improves the performance of organic photochromic compounds in the polymeric host as determined in the Photochromic Performance Test. Also described is a process for incorporating kinetic enhancing additives into polymeric substrates prior to, after and/or with organic photochromic compounds and the resulting photochromic articles produced by such a process.

Abstract: The present invention provides a powder coating composition for forming a multilayer film, obtainable by dry blending a lower layer-forming thermosetting powder coating material (A) and an upper layer-forming thermosetting powder coating material (B), wherein at least one of the following conditions is satisfied: (I) the material (A) contains an onium salt compound; (II) particles of 45 &mgr;m or smaller diameter account for at least 90 wt. % of each of the materials (A) and (B); and (III) the material (A) is higher than the material (B) in melt viscosity (Pa·s) measured at 130° C.

Abstract: A non-halogenated, fire retardant, expandable poly (arylene ether)/polystyrene blends is produced by the method comprising, in a first step, forming a fire retardant mixture comprising a non-halogenated fire retardant, poly(arylene ether) resin and polystyrene resin by intimately mixing in melt; and in a second step, forming the non-halogenated, fire retardant, expandable poly (arylene ether)/polystyrene blend by intimately mixing in melt the fire retardant mixture with a blowing agent.